Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Stock Information for Syros Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.